Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Lilly Finalizes Novartis Animal Health Acquisition

January 2, 2015
Life sciences
/PRNewswire/ – Eli Lilly and Company today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As part of the approval, certain animal health assets in the U.S. relating to the Sentinel® canine parasiticide franchise will be divested to Virbac, as has been previously announced. All other closing conditions have also been met.
 
The combined organization will increase Elanco’s product portfolio, expand its global commercial presence and deliver more innovation to customers. The acquisition also augments Elanco’s manufacturing and R&D capabilities with a total of 17 manufacturing sites and 14 R&D locations in the newly combined organization.  Further, Elanco will have a more balanced and diversified business with revenues more evenly split between food animal and companion animal, as well as stronger geographic representation.
 
“As a top-tier animal health company, we are better positioned to help our customers respond to the changing external environment and meet increasing demands for animal protein, as well as growing desires for pet ownership,” said Jeff Simmons, senior vice president of Eli Lilly and Company and president of Elanco Animal Health.  “Our combination will deliver a more comprehensive suite of existing solutions, but will also allow us to dedicate greater resources to new product discovery and development.”
 
Under the terms of the agreement, Lilly acquired the Novartis Animal Health business in an all-cash transaction of approximately $5.4 billion, including anticipated tax benefits. Lilly funded this acquisition with approximately $3.4 billion of cash-on-hand and $2.0 billion in debt. The impact of the acquisition, which closed on January 1, 2015, will be reflected in Lilly’s first quarter 2015 financial statements.
 
Source: Eli Lilly and Company

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

Read more
April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

Read more
April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

Read more
More news

How can we help you?

We're easy to reach